A recent move by US FDA clarifies protections for manufacturers that might want to discuss a device treatment regimen with an insurance company, or share suggestions about device usage that aren’t included in the labeling with physicians.
The agency announced June 12 that it finalized two question-and-answer format guidance documents related to manufacturer communications. The first addresses...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?